PRICE T ROWE ASSOCIATES INC /MD/ - REATA PHARMACEUTICALS INC ownership

REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 201 filers reported holding REATA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.11 and the average weighting 0.6%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of REATA PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$30,155
+11.6%
295,741
-0.4%
0.00%0.0%
Q1 2023$27,010
+3569.8%
297,065
+1433.7%
0.00%
Q4 2022$736
-99.8%
19,369
+1.7%
0.00%
Q3 2022$479,000
-96.9%
19,046
-96.2%
0.00%
-100.0%
Q2 2022$15,218,000
-17.5%
500,770
-11.0%
0.00%0.0%
Q1 2022$18,436,000
-27.6%
562,749
-41.7%
0.00%0.0%
Q4 2021$25,474,000
-76.0%
966,011
-8.6%
0.00%
-80.0%
Q3 2021$106,323,000
-29.5%
1,056,787
-0.8%
0.01%
-28.6%
Q2 2021$150,740,000
+43.5%
1,065,074
+1.1%
0.01%
+27.3%
Q1 2021$105,057,000
-24.2%
1,053,732
-6.0%
0.01%
-21.4%
Q4 2020$138,568,000
+54.6%
1,120,922
+21.8%
0.01%
+40.0%
Q3 2020$89,619,000
-38.2%
919,926
-1.0%
0.01%
-44.4%
Q2 2020$144,993,000
+6.1%
929,322
-1.9%
0.02%
-18.2%
Q1 2020$136,710,000
-51.3%
947,136
-31.0%
0.02%
-38.9%
Q4 2019$280,720,000
+244.7%
1,373,184
+35.4%
0.04%
+200.0%
Q3 2019$81,449,000
+32.7%
1,014,432
+56.0%
0.01%
+33.3%
Q2 2019$61,364,000
+71.3%
650,391
+55.2%
0.01%
+80.0%
Q1 2019$35,814,000
+60.4%
419,022
+5.3%
0.01%
+25.0%
Q4 2018$22,324,000
-31.3%
397,935
+0.2%
0.00%
-20.0%
Q3 2018$32,482,000397,2790.01%
Other shareholders
REATA PHARMACEUTICALS INC shareholders Q2 2021
NameSharesValueWeighting ↓
CPMG Inc 2,896,901$291,457,00032.14%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 46,646$4,693,0005.31%
Ikarian Capital, LLC 471,400$47,423,0003.34%
Duquesne Family Office 695,033$69,927,0002.27%
Camber Capital Management LP 685,000$68,918,0002.12%
LBJ Family Wealth Advisors, Ltd. 30,359$3,054,0001.82%
MADDEN SECURITIES Corp 33,127$3,333,0001.80%
Biondo Investment Advisors, LLC 104,120$10,475,0001.80%
Tolleson Wealth Management, Inc. 60,750$6,112,0001.73%
Keel Point, LLC 97,074$9,767,0001.26%
View complete list of REATA PHARMACEUTICALS INC shareholders